贝利尤单抗治疗系统性红斑狼疮出现严重感染 风险的系统评价.

OBJECTIVE: To systematically review the risk of severe infection in patients with systemic lupus erythematosus treated with belimumab. METHODS: Clinical randomized controlled trials (RCT) on belimumab in the treatment of systemic lupus erythematosus were retrieved from PubMed, the Cochrane Library, SinoMed, Ovid Embase, VIP, CNKI, Wanfang Data and other database (with a search deadline of Jul. 1st, 2022). Literature screening was performed in combination with the inclusion and exclusion criteria developed for this study, and data analysis was performed by using RevMan 5. 3 software to calculate the relative risk (RD) and their 95%CI for the risk of severe infections. RESULTS: Totally 9 clinical RCT were enrolled, including 5 174 patients. Results of Meta-analysis indicated that no statistically significant difference in the risk of serious infection between the group of belimumab combined with standard therapy and the group of placebo combined with standard therapy (RD = -0. 00, 95%CI = - 0. 01-0. 01, P = 0. 89). CONCLUSIONS: For patients with systemic lupus erythematosus, the risks of severe infection with belimumab combined with standard therapy was comparable to that with placebo combined with standard therapy; the combination of belimumab on the basis of standard therapy did not increase the risk of severe infection. [ABSTRACT FROM AUTHOR]